Molecular Partners AG (XSWX:MOLN) OCF Margin %: 0.00% (As of Mar. 2026)

What is Molecular Partners AG OCF Margin %?

Molecular Partners AG XSWX:MOLN +0.65% 29 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates XSWX:MOLN with a GF Score™ of 29/100 and a GF Value™ of CHF0.37 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 960 Biotechnology companies, Molecular Partners AG ranks worse than 104166.56% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Molecular Partners AG's Cash Flow from Operations for the three months ended in Mar. 2026 was CHF-14.24 Mil. Molecular Partners AG's Revenue for the three months ended in Mar. 2026 was CHF0.00 Mil. Therefore, Molecular Partners AG's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Molecular Partners AG's current OCF Yield % is -41.37%.

The historical rank and industry rank for Molecular Partners AG's OCF Margin % or its related term are showing as below:

During the past 13 years, the highest OCF Margin % of Molecular Partners AG was 62.55%. The lowest was -1192.11%. And the median was -310.18%.

XSWX:MOLN's OCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -68.59
* Ranked among companies with meaningful OCF Margin % only.

Molecular Partners AG OCF Margin % Related Terms

Molecular Partners AG OCF Margin % Historical Data

* Premium members only.

The historical data trend for Molecular Partners AG's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Molecular Partners AG OCF Margin % Chart

Molecular Partners AG Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

OCF Margin %

Get a 7-Day Free Trial

-974.84

62.55

-838.38

-1,192.11

0.00

Molecular Partners AG Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
OCF Margin %	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

29GF Score

Molecular Partners AG XSWX:MOLN

OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Molecular Partners AG OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Molecular Partners AG's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin	=	Cash Flow from Operations (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-51.257	/	0
	=	%

Molecular Partners AG's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin	=	Cash Flow from Operations (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-14.243	/	0
	=	%

Frequently Asked Questions Learn more about OCF Margin % →

What does a OCF Margin % of 0.00% mean?

Molecular Partners AG (XSWX:MOLN) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Molecular Partners AG and its competitors. According to the industry distribution chart, Molecular Partners AG ranks #999999 out of 960 companies in the Biotechnology industry.

Is Molecular Partners AG's OCF Margin % too high?

Molecular Partners AG's current OCF Margin % is 0.00%. Based on the distribution chart, Molecular Partners AG ranks #999999 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Molecular Partners AG has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Molecular Partners AG's OCF Margin % compare to VRTX and REGN?

According to the Biotechnology industry distribution chart, Molecular Partners AG ranks #999999 out of 960 companies for OCF Margin %. This places Molecular Partners AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good OCF Margin % for a Biotechnology company?

A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high OCF Margin % mean?

A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Molecular Partners AG and its competitors. Molecular Partners AG's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Molecular Partners AG stock overvalued right now?

Based on GuruFocus' analysis, Molecular Partners AG (XSWX:MOLN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF0.37, compared to a current price of CHF3.12 — trading 743.2% above its estimated fair value. The current OCF Margin % is 0.00%. Molecular Partners AG's overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is OCF Margin % calculated?

OCF Margin % is calculated from a company's financial statements. For Molecular Partners AG (XSWX:MOLN), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Molecular Partners AG (XSWX:MOLN) Overvalued in 2026?

Based on GuruFocus' analysis, Molecular Partners AG stock appears to be overvalued. The current stock price of CHF3.12 is trading 743.2% above its estimated GF Value™ of CHF0.37. GuruFocus considers Molecular Partners AG to be Significantly Overvalued.

Key valuation signals for XSWX:MOLN:

OCF Margin %: 0.00%
GF Value™: CHF0.37 vs. price of CHF3.12 (743.2% above fair value)
GF Score™: 29/100 with 3 warning signs

No single metric tells the full story. See the XSWX:MOLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Molecular Partners AG Business Description

Industry Healthcare Biotechnology

Comparable Companies XSWX:XLS XSWX:BIOV XSWX:MMTX XSWX:ADXN XSWX:SANN XSWX:NWRN VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270 RPRX BNTX INSM ROIV

Other Exchanges MOLN:USA MLLCF:USA MOLNz:UK 0QXX:UK 6ML:Germany

Address Wagistrasse 14, Schlieren, Zurich, CHE, 8952

Website https://www.molecularpartners.com

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.

29GF Score

Get the complete analysis for XSWX:MOLN

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF3.12

Price

CHF0.37

GF Value

View XSWX:MOLN Analysis

See OCF Margin % data for all stocks →